drugset / Trial / NCT04123314
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Phase 0
Recruiting
20 enrolled
Johns Hopkins University
Council On Spiritual Practices · collabHeffter Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Timeline
- Start
- 2021-03-24
- Primary completion
- 2026-09-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 15 mg/kg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg/kg | — |